# Augmenix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/augmenix

- Industry: Medical Devices & Equipment
- Headquarters: Bedford, US
- Website: www.augmenix.com
- Total disclosed funding: $17M
- Latest round: Series D (Jul 22, 2014)
- Investors on record: 6

## About

Augmenix, Inc. specializes in innovative medical devices, focusing on improving patient outcomes for prostate cancer treatment through its unique hydrogel technology.Founded in 2008 and headquartered in Bedford, US, Augmenix, Inc. develops medical devices that enhance radiation therapy for prostate cancer patients. The company has undergone strategic transitions, culminating in a significant acquisition by Boston Scientific Corporation in September 2018 for USD 500 mn, with an additional USD 100 mn in milestone payments. Daksh Thapar is the CEO of Augmenix, Inc. The company has successfully completed 8 funding deals, with the most recent deal occurring on September 6, 2018.The core offering of Augmenix, Inc. is the SpaceOAR™ Hydrogel, a proprietary polyethylene glycol (PEG)-based hydrogel intended for prostate cancer patients undergoing radiation therapy. This product creates a temporary space between the rectum and prostate, minimizing radiation exposure to the rectum and reducing side effects such as urinary, sexual, and bowel dysfunction. SpaceOAR Hydrogel has been utilized by over 50,000 patients globally, with primary end-users including prostate cancer patients and clients like hospitals, cancer treatment centers, and urologists across North America, Europe, and Asia.Augmenix, Inc. generates revenue through the sale of SpaceOAR Hydrogel to healthcare providers, enabling them to offer this treatment to patients during radiation therapy. The B2B sales model involves hospitals and urology clinics purchasing the hydrogel directly, with pricing structures based on agreements that consider the product's clinical effectiveness and support provided to medical staff. The company relies on a strong network of partnerships with medical professionals and institutions to integrate SpaceOAR Hydrogel into standard prostate cancer treatment protocols.Following its acquisition by Boston Scientific in October 2018, Augmenix, Inc. plans to leverage this partnership to enhance its product offerings and expand into new markets. The company is targeting growth in Europe and Asia by the end of 2023, alongside ongoing development of additional innovative products aimed at improving patient care in radiation therapy. The recent acquisition funding will facilitate these initiatives, including the development of new treatment protocols and expanding the distribution of SpaceOAR Hydrogel.

## Funding rounds

- Series D, Jul 22, 2014, $11M — Catalyst Health Ventures, Ascension Ventures, Sparta Group, Excelestar Ventures
- Series B, Oct 16, 2009, $6.1M — Versant Ventures, Pinnacle Ventures, Catalyst Health Ventures, Ascension Ventures

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series B
- Pinnacle Ventures (https://capitalatlas.ai/funds/pinnacle-ventures) — Series B
- Catalyst Health Ventures (https://capitalatlas.ai/funds/catalyst-health-ventures) — Series B, Series D
- Ascension Ventures (https://capitalatlas.ai/funds/ascension-ventures) — Series B, Series D
- Sparta Group — Series D
- Excelestar Ventures (https://capitalatlas.ai/funds/excelestar-ventures) — Series D